N-甲基-D-天冬氨酸受体显像剂研究进展

N-甲基-D-天冬氨酸(NMDA)受体已成为发展帕金森病、阿尔茨海默病、精神分裂症、癫痫、亨廷顿舞蹈症等神经变性疾病药物的新靶点.NMDA受体显像剂的研制将为神经变性疾病的早期诊断和治疗提供灵敏的分子探针和特异的诊断方法.多数NMDA受体显像剂因脂溶性和亲和力欠佳而不宜用于临床,有希望成为NMDA受体显像剂的是123I-CNS1261.该文综述了近年来关于NMDA受体显像剂的研究进展.     

18F-FECNT的生物分布特性及小动物PET显像研究

Objective 2β-carbomethoxy-3β-(4-corophenyl)-8-(2-18F-fluoroethyl) nortropane (18F-FECNT) is a recently developed dopamine transporter (DAT) imaging agent. The aim of this study was to evaluate its brain biedistribution and to assess its usefulness in quantitation of DAT density in normal and hemiparkinsonian rats. Methods Six groups of mice (5 mice each group) received 18F-FECNT were sacri-ficed at indicated time post injection. Different brain regions (cortex, hippocampus, striatum, cerebellum) were removed, weighed, and countered. DAT blocking effect was investigated in mice pretreated with 2β-Carbomethoxy-3β-(4-fluorpbenyl)tropane (β-CFT) at before 18F-FECNT injection. MicroPET scans were performed in beth normal and unilaterally 6-hydroxydopamine-lesioned rats. Results The brain uptake of 18F-FECNT was 2.22, 1.20, 1.02, 0.78, 0.71, and 0.67 percent injection dose (%ID) at 5, 15, 30, 60, 120, and 180 min post injection. Radioactivity concentration of the striatum, the target region, was the highest in the brain regions and decreased quickly from 5 to 60 min and reached to background at 120 min of post injection. The striatum/cerebellum ratio was 2.56, 3.47, 2.78, 1.63, 0.97, and 0.88 at 5, 15, 30, 60, 120, and 180 min, respectively, post injection. The selective striatum uptake of 18F-FECNT decreased dramatically to the background when the DAT was blocked with β-CFT. The striatum of normal rats in micro-PET exhibited symmetrical (left/right = 1.00±0.05) and the highest uptake of radioactivity (striatum/cere-helium =2.18±0. 16 at 5- 125 min, n =3). As for the hemiparkinsonian rats, nonsymmetrical [unlesioned striatum/cerebellum vs lesioned striatum/cerebellum = 2.01 ± 0.23 (n = 3) vs 1.04 ± 0. 05] and the high-est uptake of radioactivity were also noted. Conclusions The results suggest that 18F-FECNT rapidly pas-ses through blood-brain barrier and locates in stiatal region with high affinity and selectivity to DAT. It is a potential radiotracer to assess the in vivo DAT density in Parkinson's disease.     

HPLC法同时测定注射用甲氧异腈中FSA和MIBI的含量

目的:采用RP-HPLC法同时测定了注射用甲氧异腈中两种主要成份二氧硫脲(FSA)和四(甲氧基异丁基异腈)络铜(I)氟硼酸盐(MIBI)的含量。方法:以甲醇、磷酸二氢铵( 80∶2 0 )为流动相,检测波长215nm ,HPLC法测定含量。结果:试验表明,FSA和MIBI在25～125μg/ml,50～250μg/ml范围内呈良好的线性关系,回归方程分别为Y=0.23+0.02X(r=0.9946) ,Y=-2.19+0.03X(r=0.9998) ,相对标准偏差分别为1.25%和0.42%。结论:该方法简便、准确、可靠     

美金刚胺片的HPLC-ELSD测定

建立了HPLC-ELSD测定美金刚胺片中盐酸美金刚胺的含量.采用C18柱,流动相为甲醇-水-三乙胺(80:20:0.1).盐酸美金刚胺在100～500μg/ml范围内线性关系良好(r2=0.9994),平均加样回收率为101.6%.     

N-甲基-D-天冬氨酸受体显像剂研究进展

N-甲基-D-天冬氨酸(NMDA)受体已成为发展帕金森病、阿尔茨海默病、精神分裂症、癫痫、亨廷顿舞蹈症等神经变性疾病药物的新靶点.NMDA受体显像剂的研制将为神经变性疾病的早期诊断和治疗提供灵敏的分子探针和特异的诊断方法.多数NMDA受体显像剂因脂溶性和亲和力欠佳而不宜用于临床,有希望成为NMDA受体显像剂的是123I-CNS1261.该文综述了近年来关于NMDA受体显像剂的研究进展.     

注射用重组人甲状旁腺素代谢产物PTH(1-34)的测定及其药动学

目的:注射用重组人甲状旁腺素PTH(1-84)在体内的代谢产物PTH(1-34)对骨质疏松症具有较好的疗效,本试验通过测定人血浆中PTH(1-34)浓度的变化,了解PTH(1-34)在体内的分布,对注射用重组人甲状旁腺素PTH(1-84)的药效及作用机制具有重要意义。方法:采用固相萃取法结合放射免疫分析(RIA)测定人血浆中注射用重组人甲状旁腺素代谢产物PTH(1-34)的浓度,采用DAS2.0数据处理系统进行药动学分析。结果:PTH(1-34)的线性范围为10～1 280 pg.mL-1,最低检测限为10 pg.mL-1(RSD为3.51%),采用固相萃取柱Styre Screen H2P在血浆样本萃取效率大于85%。结论:本法测定注射用重组人甲状旁腺素在血浆中的代谢产物PTH(1-34)的方法是可行的,特异性、灵敏度、精密度和准确度较高,可应用于临床样本的检测。     

顶空气相色谱法测定依匹必利原料药中有机溶剂残留量

目的:建立以顶空气相色谱法测定依匹必利原料药中3种有机溶剂甲醇、乙醚、三乙胺残留量的方法。方法:采用顶空进样法,以二甲基甲酰胺为溶剂,甲苯为内标,平衡温度70℃,平衡时间30min。气相色谱条件中采用OV1701色谱柱;程序升温:40℃维持2min,以5℃·min-1的速率升至180℃,维持10min;气化室温度为200℃,检测器温度为260℃;载气为氮气,流速为5mL·min-1。结果:甲醇、乙醚、三乙胺检测浓度线性范围分别为53.8～376.6、62.0～434.0、20.2～141.4μg·mL-1(r均>0.9949);回收率均>98.1%,RSD均<1.9%。样品中3种有机溶剂残留量甲醇<0.092%、乙醚<0.0021%、三乙胺<0.00015%。结论:所建立方法灵敏、准确、可靠,适用于依匹必利原料药中有机溶剂残留量的测定。     

N-甲基-D-天冬氨酸受体显像剂研究进展

N-甲基-D-天冬氨酸(NMDA)受体已成为发展帕金森病、阿尔茨海默病、精神分裂症、癫痫、亨廷顿舞蹈症等神经变性疾病药物的新靶点.NMDA受体显像剂的研制将为神经变性疾病的早期诊断和治疗提供灵敏的分子探针和特异的诊断方法.多数NMDA受体显像剂因脂溶性和亲和力欠佳而不宜用于临床,有希望成为NMDA受体显像剂的是123I-CNS1261.该文综述了近年来关于NMDA受体显像剂的研究进展.